Evaluation of transsphenoidal hypophysectomy in the management of patients with advanced malignant melanoma

Transsphenoidal hypophysectomy was performed in 13 patients with advanced malignant melanoma. Although three minor responses were observed, there were no complete or partial responses. All three patients with bone pain had a decrease in discomfort lasting 1–2 months. All five patients with minor responses or stable disease had postoperative decreases in the excretion of the dihydroxyphenylalanine (DOPA) metabolite 3‐O‐methyldopamine; all but one patient with clinical progression had postoperative increases in excretion. Average survival of those whose postoperative excretion fell (143+ days; range, 60–217+) was significantly longer (P < 0.004) than that of those whose postsurgical values rose (30 days; range, 15–58).

[1]  V. Camp,et al.  Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine. , 1981, Clinical chemistry.

[2]  B. T. Lim,et al.  Serum tyrosinase in malignant disease, its activity, and the electrophoretic patterns of the enzyme as carried by immunoglobulins'. , 1979, Cancer research.

[3]  G. Tindall,et al.  Transsphenoidal hypophysectomy for disseminated carcinoma of the prostate gland. Results in 53 patients. , 1979, Journal of neurosurgery.

[4]  G. Todaro,et al.  Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Pawelek.  Evidence suggesting that a cyclic AMP‐dependent protein kinase is a positive regulator of proliferation in Cloudman S91 melanoma cells , 1979, Journal of cellular physiology.

[6]  V. Camp,et al.  Development of an Enzyme-Radioimmunoassay for the Measurement of Dopamine in Human Plasma and Urine , 1978 .

[7]  W. Chavin,et al.  Glucocorticoid modulation of adrenocorticotropin-induced melanogenesis in the Cloudman S-91 melanoma in vitro. , 1978, Experimental cell biology.

[8]  E. Rosengren,et al.  5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations. , 1977, European journal of cancer.

[9]  V. Camp,et al.  The measurement of 3-o-methyldopamine in urine and plasma by a rapid and specific radioimmunoassay. , 1977, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  R. Halaban,et al.  Tyrosinase and inhibition of proliferation of melanoma cells and fibroblasts. , 1977, Experimental cell research.

[11]  R. Halaban,et al.  The dual effect of melanocyte-stimulating hormone (MSH) on the growth of cultured mouse melanoma cells. , 1977, Experimental cell research.

[12]  M. S. Blois,et al.  Column cation-exchange separation of melanin-related metabolites in urine from cases of melanoma. , 1977, Clinical chemistry.

[13]  G. Silverberg.  Hypophysectomy in the treatment of disseminated prostate carcinoma , 1977, Cancer.

[14]  G. Todaro,et al.  Nerve growth factor receptors on human melanoma cells in culture. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Fisher,et al.  ŒSTROGEN RECEPTORS IN HUMAN MALIGNANT MELANOMA , 1976, The Lancet.

[16]  E. Rosengren,et al.  Catechols in primary and metastatic human malignant melanoma cells in monolayer culture. , 1976, European journal of cancer.

[17]  G. Tindall,et al.  Hypophysectomy in the Treatment of Disseminated Carcinoma of the Breast and Prostate Gland , 1976, Southern medical journal.

[18]  M. Schwartz.  Biochemistry of malignant melanoma. , 1976, Annals of clinical and laboratory science.

[19]  V. Yavorsky,et al.  Clinical evaluation of a method of quantitative determination of homovanillic acid for the estimation of degree of tumor dissemination process in melanoma of the skin , 1975 .

[20]  T. Lincoln,et al.  The role of adenosine 3′,5′‐monophosphate in the transformation of cloudman mouse melanoma cells , 1975, Journal of cellular physiology.

[21]  P. Cuatrecasas,et al.  Cholera toxin mimics melanocyte stimulating hormone in inducing differentiation in melanoma cells. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Pawelek,et al.  Molecular biology of pigment cells. Molecular controls in mammalian pigmentation. , 1973, The Yale journal of biology and medicine.

[23]  G. Tolis,et al.  Functional evaluation of prolactin secretion in patients with hypothalamic-pituitary disorders. , 1973, The Journal of clinical investigation.

[24]  R. J. Bartholomew,et al.  Precursors of melanin in the blood and urine in malignant melanoma. , 1972, Clinica chimica acta; international journal of clinical chemistry.

[25]  H. Käser,et al.  Quantitative fluorimetric determination of urinary dopa and its significance for the diagnosis of neural crest tumours. , 1971, Clinica chimica acta; international journal of clinical chemistry.

[26]  R. Richterich,et al.  Increased urinary dihydroxyphenylalanine oxidase activity in patients suffering from malignant melanoma. , 1970, Clinica chimica acta; international journal of clinical chemistry.

[27]  M. Voorhess.  Urinary excretion of DOPA and metabolites by patients with melanoma , 1970, Cancer.

[28]  W. Collins,et al.  Results of trans-sphenoidal cryohypophysectomy for carcinoma of the breast. , 1969, The New England journal of medicine.

[29]  T. Kapur,et al.  Trans‐sphenoidal hypophysectomy for metastatic carcinoma of the breast , 1969, The British journal of surgery.

[30]  G. Edelstyn,et al.  Total hypophysectomy for advanced breast cancer. , 1968, Clinical radiology.

[31]  R. Straffon,et al.  90-yttrium hypophysectomy in the management of metastatic carcinoma of the prostate gland in 13 patients. , 1968, The Journal of urology.

[32]  B. Ray.  Hypophysectomy as Palliative Treatment , 1967 .

[33]  Ray Bs.  Current cancer concepts. Hypophysectomy as palliative treatment. , 1967, JAMA.

[34]  Debono Ah.  PSYCHIATRIC UNITS IN GENERAL HOSPITALS. , 1964 .

[35]  T. Fitzpatrick,et al.  QUANTITATIVE DETERMINATION OF DOPA; ITS APPLICATION TO MEASUREMENT OF DOPA IN URINE AND IN THE ASSAY OF TYROSINASE IN SERUM. , 1964, The Journal of investigative dermatology.

[36]  J. Duchon̆,et al.  THE BIOCHEMICAL AND CLINICAL SIGNIFICANCE OF MELANOGENURIA , 1963 .

[37]  J. D. Fergusson,et al.  A clinical evaluation of radioactive pituitary implantation in the treatment of advanced carcinoma of the prostate. , 1962, British journal of urology.

[38]  J. A. Scott.  3,4-dihydroxyphenylalanine (DOPA) excretion in patients with malignant melanoma. , 1962, Lancet.

[39]  B. Ray,et al.  Hypophysectomy in the treatment of metastatic mammary cancer. , 1960, American journal of surgery.

[40]  B. Kennedy,et al.  Hypophysectomy in advanced breast cancer. , 1965, The New England journal of medicine.

[41]  E. Boldrey,et al.  Effects of surgical hypophysectomy in a man with malignant melanoma. , 1952, The Journal of clinical endocrinology and metabolism.

[42]  M. Shimkin,et al.  Irradiation of the normal human hypophysis in malignancy: report of three c cases receiving 8,100-10,000 r tissue dose to the pituitary gland. , 1951, Journal of the National Cancer Institute.